AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2025
Dec 17, 2025
31523_dirs_2025-12-17_c233d9ba-7d48-4f74-87ea-3ec1a1e18f19.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2025-12-15
Reporting Person: Campbell Bradley L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-15 | Common Stock | M | 70426 | $9.03 | Acquired | 1207708 | Direct |
| 2025-12-15 | Common Stock | S | 77926 | $10.8566 | Disposed | 1129782 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | Stock Options (right to buy) | $9.03 | M | 70426 | Disposed | 2026-01-04 | Common Stock (70426) | Direct |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.60 to $11.11 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: All of the options were fully vested and exercisable as of the transaction date.